Clinical Trial Update: Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of endoluminal high-dose-rate brachytherapy with concurrent chemotherapy for rectal or anal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Cancer
• Rectal Cancer

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Rectal or Anal Cancer | Phase 1 | Status: COMPLETED